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The “silent epidemic” of viral hepatitis affects a large part of the world’s population without 
due attention from the health sector. Now, however, co-infection with HIV and viral hepatitis is 
increasingly recognized as a considerable public health problem. 
It is estimated that 240 million people are chronically infected with hepatitis B (HBV) and 
170 million are chronically infected with hepatitis C (HCV). These numbers far exceed the number 
of people living with HIV, estimated at 34 million. 
People who inject drugs (PWID) are a key population affected by HBV and HCV. There are 
approximately 16 million people who inject drugs in 148 countries (1). In 2011 it was estimated 
that 1,2 million people who inject drugs are infected with HBV and 10 million people who inject 
drugs are infected with HCV(2).
Around the world, the prevalence of HBV among people who inject drugs correlates with the 
prevalence in the general population. The highest prevalence rates of HBV among the general 
population and people who inject drugs are found in Asia. On average, HCV prevalence among 
people who inject drugs is higher than 50% in most countries of the world, between 60% and 
80% in 25 countries, and above 80% in a further 12 countries (2). The largest populations of 
injecting drug users live in China (HCV prevalence estimated at 67% of people who inject drugs), 
the Russian Federation (73%) and the United States (72%).
The global response to viral hepatitis B and C has been poor. For people who inject drugs, HBV 
and HCV are most commonly transmitted by sharing contaminated injecting equipment. Despite 
the recommendation to implement needle and syringe programmes as a key public health measure 
(3), many countries with injecting drug use do not provide these programmes, and coverage levels 
are generally not sufficient in countries that do provide sterile injecting equipment. It is estimated 
that globally only 22 syringes are provided per year per person who injects drugs (4). 
Although the HBV vaccine is inexpensive, safe and effective, vaccination rates for HBV among 
people who inject drugs are lower than in the general population. There is a need to improve HBV 
vaccination rates in people who inject drugs. There is currently no vaccine for HCV; hence, there is 
an urgent need to identify additional measures to prevent transmission of HCV in this population.
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RecOmmendatiOn 1
it is suggested to offer people who inject drugs the rapid 
hepatitis B vaccination regimen.*
RecOmmendatiOn 2
it is suggested to offer people who inject drugs incentives 
to increase uptake and completion of the hepatitis B 
vaccine schedule.†
RecOmmendatiOn 3
it is suggested that needle and syringe programs also 
provide low dead-space syringes for distribution to people 
who inject drugs.‡
RecOmmendatiOn 4
Psychosocial interventions are not suggested for people 
who inject drugs to reduce the incidence of viral hepatitis.
RecOmmendatiOn 5
it is suggested to offer peer interventions to people who 
inject drugs to reduce the incidence of viral hepatitis
This Guidance on prevention of viral hepatitis B and C among 
people who inject drugs (5) is the first step in the provision of com-
prehensive guidance on viral hepatitis surveillance, prevention and 
treatment by the World Health Organization. These recommendations 
are based on systematic reviews of scientific evidence, community 
values and preferences and implementation issues. Although the 
focus of this guidance is on low- and middle-income countries, this 
guidance applies equally to high-income settings. 
The WHO, UNODC, UNAIDS technical guide for countries to set 
targets for universal access to HIV prevention, treatment and care 
for injecting drug users (3) presents a comprehensive package of 
interventions for HIV prevention, treatment and care for people who 
inject drugs. This document has helped to achieve global consensus 
with high-level political bodies, the United Nations, donor agencies 
and civil society organizations on adopting a public health response 
that best addresses HIV in countries facing epidemics of injecting 
drug use. The nine interventions of this package (see above) are also 
relevant to the prevention of viral hepatitis, in particular the first two, 
needle and syringe programmes and opioid substitution therapy.
the nine inteRventiOns in the 
cOmPRehensive Package
1 needle and syringe programmes 
2 opioid substitution therapy and other 
drug dependence treatment
3 hiv testing and counselling 
4 antiretroviral therapy 
5 prevention and treatment of sexually 
transmitted infections 
6 condom programmes for people who 
inject drugs and their sexual partners
7 targeted information, education and 
communication for people who inject 
drugs and their sexual partners
8 vaccination, diagnosis and treatment of 
viral hepatitis
9 prevention, diagnosis and treatment of 
tuberculosis.
summaRy OF RecOmmendatiOns
* A higher dose HBV vaccine should be used with the rapid regimen; standard and rapid regimens should be 
offered to PWID, with first priority given to delivery of the first dose and then to completion of three doses.
† This recommendation is conditional on local acceptability and resource availability; vaccinations should be 
provided at a location and time convenient for PWID.
‡ Syringe programmes should offer all types of syringes appropriate for local needs.
lOW dead-sPace syRinges
Low dead-space syringes (LDSS) are designed to reduce the amount of 
blood remaining in the syringe after completely pushing down the syringe 
plunger. LDSS commonly have a non-detachable needle joined directly to 
the syringe barrel. The amount of blood remaining in a LDSS after pushing 
down the syringe plunger and rinsing the syringe is up to 100-fold less 
than that remaining in an ordinary syringe with high dead space. Studies 
have shown that this difference in dead space reduces the survival of 
HCV and HIV in blood remaining in syringes. The implication is a potential 
reduction in risk of transmission of HCV and HIV when syringe-sharing 
takes place. The evidence for the effectiveness of LDSS in reducing HCV 
transmission among people who inject drugs was reviewed. Given the 
limited literature available, HIV transmission was interpreted as a proxy 
for HCV transmission. The evidence indicated that providing LDSS leads 
to a reduction in the transmission of HIV and HCV and that needle and 
syringe programmes should also provide LDSS in addition to all types of 
syringes appropriate for local needs.
hePatitis B vaccinatiOn
HBV vaccination is inexpensive, safe and effective. The standard schedule for HBV vaccination is at 0, 1, and 6 months, 
while the rapid schedule is at 1, 7, and 21 days. By 2008, 177 countries had incorporated HBV vaccination into their 
national schedule of childhood immunizations. An estimated 69% of the 2008 birth cohort received three doses of 
the vaccine. The implication of this high immunization rate is that HBV vaccination for people who inject drugs and 
other high-risk groups is a time-limited challenge, as new cohorts of people who inject drugs increasingly will have 
been immunized at birth. Nevertheless, in many parts of the world HBV vaccination rates among people who inject 
drugs are low, for a variety of reasons including cost, access and the unsettled lives of many people who inject drugs. 
Systematic reviews examined HBV vaccine completion and uptake when the rapid HBV vaccine schedule is offered 
and, separately, when incentives are offered. Evidence showed that both the rapid schedule as well as providing 
incentives to people who inject drugs helped increase uptake and completion of HBV vaccination. Vaccinations should 
be provided at a location and time convenient for people who inject drugs.
PsychOsOcial inteRventiOns
Psychosocial interventions, also known as behavioural interventions, aim to change behaviour through the exchange of 
information, typically lead by a clinician or educator. They include, but are not limited to, brief interventions, motivational 
interviewing, cognitive behavioural therapy, contingency management, behavioural therapy and self-help groups. 
Psychosocial interventions are used as therapy in a number of health disciplines, including the treatment of substance 
use disorders. Based on the results of systematic reviews, psychosocial interventions cannot be suggested as a core 
intervention because no evidence was found that they reduce rates of viral hepatitis transmission.
PeeR inteRventiOns
Peer interventions—initiatives that include peers in service delivery, also termed peer-based or peer-driven 
interventions—are often an aspect of outreach initiatives. Peer interventions for people who inject drugs are common 
in many parts of the world where there is injecting drug use. The evidence of the effectiveness of peer interventions to 
reduce HBV and HCV transmission as well as to change injecting and sexual risk behaviour was reviewed. In contrast 
to other psychosocial interventions, delivered by health workers, evidence showed that interventions delivered by 
peers were effective in reducing transmission of viral hepatitis.
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PRinciPles and imPlementatiOn 
• The principles for this guidance, and for working with people who inject drugs, are the protection of human rights, 
access to health care, access to justice, acceptability of services, health literacy and integrated service provision. 
Interventions must be acceptable and appropriate for people who inject drugs. Consultation and cooperation 
with drug user groups is important when designing and implementing services.
• This guidance should be implemented in phases, consistent with the level of resources available. Consideration 
should be given to building awareness of this guidance among health-care workers and people who inject 
drugs. For the implementation of these guidelines, the local context of health systems, prevention services and 
community involvement should be considered. 
next stePs
This guidance will be updated in future in accordance with WHO policy. In 
addition, WHO is currently developing guidance on viral hepatitis surveillance, 
guidance on hepatitis C treatment and guidance on the management of HIV in 
the context of co-infection with viral hepatitis and HIV.
Multisectoral engagement is needed to increase the uptake of viral hepatitis 
prevention and treatment initiatives by people who inject drugs. There is a high 
prevalence of disease co-morbidity among people who inject drugs. The need 
for coordination between HBV and HCV intervention programmes, on one 
hand, and, on the other, HIV, TB, mental health and drug dependence treatment 
services as well as harm reduction services for people who inject drugs cannot 
be overemphasized. 
it is crucial to implement 
and scale up needle and 
syringe programmes and 
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